glp-1 long term safety receptor agonism: a transformative approach for managing type-2 diabetes and obesity | Saudi Pharmaceutical Journal The GLP-1 Trap: Your Jumpstart

Missing doses or injecting too frequently can affect the medications efficacy and safety

In general, without knowing what Medicaid and Medicare generally are currently paying for these drugs on net, it is uncertain whether the lower prices that will be made available to state Medicaid programs and Part D plans under the BALANCE Model for currently covered uses of GLP-1s will generate enough savings to offset the additional costs from expanded use of these medications for obesity

Access issues have major consequences

PMID: 17498508 DOI: 10.1053/j.gastro.2007.03.054 Boer GA et al (2023): Obesity pharmacotherapy: incretin action in the central nervous system

Metabolic disorder in alzheimers disease